While these studies propose cathepsin B as a potential biomarker for predicting cancer progression in OSCC, they acknowledge limitations, such as small sample sizes and the absence of patients with benign lesions or other chronic inflammatory oral diseases [19]. Here, CTSB is linked to cancer.